Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2016

01-07-2016 | Progress in Hematology

Gene and virotherapy for hematological malignancies

Authors: Evidio Domingo-Musibay, Masato Yamamoto

Published in: International Journal of Hematology | Issue 1/2016

Login to get access

Abstract

Recent years have seen a transformation in the treatment of hematological malignancies. Advances in gene therapy and molecular techniques and significant gains in computational abilities have supported the rapid development of safer and better tolerated therapies for many patients with hematologic cancers. In this review, we discuss novel applications of gene therapy, including immunomodulation and gene silencing, and report on the rise of oncolytic viruses for use in the treatment of malignancies arising in cells of the blood, lymph, and marrow. We discuss the relationship of the tropism of wildtype viruses and their oncolytic behavior as well as the tumoricidal and immunostimulatory properties of a number of attenuated and recombinant viruses currently in clinical development in countries around the world. While we have focused on promising virotherapy applications for future development, we also present a historical perspective and identify areas of potential clinical and regulatory practice change. We outline several of the virus systems being developed for applications in hematology, and summarize efficacy data in the context of ongoing or future human clinical testing. We also present the advantages and limitations of gene and virus therapy, including challenges and opportunities for improved treatment tolerability and outcomes for patients with hematologic malignancies.
Literature
1.
Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 1944;79(2):137–58.CrossRefPubMedPubMedCentral
2.
Kay ER. Incorporation of deoxyribonucleic acid by mammalian cells in vitro. Nature. 1961;191:387–8.CrossRefPubMed
3.
Munyon W, et al. Transfer of thymidine kinase to thymidine kinaseless L cells by infection with ultraviolet-irradiated herpes simplex virus. J Virol. 1971;7(6):813–20.PubMedPubMedCentral
4.
Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci USA. 1984;81(20):6349–53.CrossRefPubMedPubMedCentral
5.
Blaese RM, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475–80.CrossRefPubMed
6.
Karlsson S. Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood. 1991;78(10):2481–92.PubMed
7.
Bregni M, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood. 1992;80(6):1418–22.PubMed
8.
Choudhury BA, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93(3):780–6.PubMed
9.
Cignetti A, et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood. 1999;94(6):2048–55.PubMed
10.
Serafini P, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64(17):6337–43.CrossRefPubMed
11.
Smith BD, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16(1):338–47.CrossRefPubMedPubMedCentral
12.
13.
Medzhitov Ruslan AI. Toll-like receptor control of the adaptive immune responses. Nat Immun. 2004;5(10):987–95.CrossRef
14.
Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102(7):2660–9CrossRefPubMed
15.
Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002;109(10):1351–9CrossRefPubMedPubMedCentral
16.
Brackett CM, et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci USA. 2016;113(7):E874–83.CrossRefPubMedPubMedCentral
17.
Kadayakkara DK, Korrer MJ, Bulte JW, Levitsky HI. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging. Cancer Res. 2015;75(1):51–61.CrossRefPubMed
18.
Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol. 2007;81(16):8666–76CrossRefPubMedPubMedCentral
19.
Derdak SV, et al. Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci USA. 2006;103(35):13144–9.CrossRefPubMedPubMedCentral
20.
Palena C, et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood. 2005;106(10):3515–23.CrossRefPubMedPubMedCentral
21.
Wen XY, et al. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther. 2001;8(5):361–70.CrossRefPubMed
22.
Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7–1 in an immunocompetent murine model. Clin Cancer Res. 2006;12(19):5859–68CrossRefPubMed
23.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.CrossRefPubMed
24.
Fire A, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–11.CrossRefPubMed
25.
Cleary DS, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol. 2004;23(2):227–31.PubMed
26.
Morris KV, et al. Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 2004;305(5688):1289–92.CrossRefPubMed
27.
28.
Choung S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342(3):919–27.CrossRefPubMed
29.
Weinstein S, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci USA. 2016;113(1):E16–22.CrossRefPubMed
30.
Sato Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–42.CrossRefPubMed
31.
Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, Li M, Carrier E, Garcia B, Jevnikar AM, Min WP. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood. 2009;113(12):2646–54CrossRefPubMed
32.
Khoury M, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 2006;54(6):1867–77.CrossRefPubMed
33.
Han J, Kim D, Morris KV. Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proc Natl Acad Sci USA. 2007;104(30):12422–7.CrossRefPubMedPubMedCentral
34.
35.
Tesniere A, et al. In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. Cell Cycle. 2010;9(14):2830–5.CrossRefPubMed
36.
Loiseau P, et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13(8):965–74.CrossRefPubMed
37.
Marmont AM, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78(8):2120–30.PubMed
38.
Georgoudaki AM, Sutlu T, Alici E. Suicide gene therapy for graft-versus-host disease. Immunotherapy. 2010;2(4):521–37.CrossRefPubMed
39.
40.
Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61(7):3022–6.PubMed
41.
Bonini C, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719–24.CrossRefPubMed
42.
Fabio C, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study. Lancet Oncol. 2009;10(5):489–500.CrossRef
43.
Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247–54CrossRefPubMedPubMedCentral
44.
45.
Wang X, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255–63.CrossRefPubMedPubMedCentral
46.
Introna M, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11(4):611–20.CrossRefPubMed
47.
Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA advisory committee symposium held 15 June 2010. Cancer Res. 2011;71(9):3175–81CrossRefPubMedPubMedCentral
48.
49.
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–9.PubMed
50.
Huebner RJ, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9(6):1211–8.CrossRefPubMed
51.
Huebner RJ, et al. Studies of adenoidal–pharyngeal–conjunctival vaccines in volunteers. J Am Med Assoc. 1955;159(10):986–9.CrossRefPubMed
52.
Bluming AZ, Ziegler JL. Regression of Burkitt’s lymphoma in association with measles infection. Lancet. 1971;2(7715):105–6.CrossRefPubMed
53.
54.
Shashkova EV, et al. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther. 2007;15(3):598–607.CrossRefPubMed
55.
Kishimoto H, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12(10):1213–9.CrossRefPubMed
56.
Prestwich RJ et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. 2008.
57.
58.
Andtbacka RH, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.CrossRefPubMed
59.
Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244–5.CrossRefPubMed
60.
61.
Dicke KA, et al. Autologous bone marrow transplantation in acute leukemia. Surv Synth Pathol Res. 1985;4(1):84–96.PubMed
62.
Breems DA, Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol. 2007;44(4):259–66.CrossRefPubMed
63.
Spellberg B, Schiller GJ. Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin N Am. 1999;13(5):919–38.CrossRef
64.
Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med. 1987;57(1):79–81.PubMed
65.
Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines. 2010;9(11):1275–302.CrossRefPubMed
66.
Billett AL, Sallan SE. Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging. Am J Pediatr Hematol Oncol. 1993;15(2):162–8.CrossRefPubMed
67.
Kim M, et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia. 2009;23(12):2313–7.CrossRefPubMedPubMedCentral
68.
Adachi Y, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res. 2001;61(21):7882–8.PubMed
69.
Wang G, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA. 2006;103(12):4640–5.CrossRefPubMedPubMedCentral
70.
Yamamoto M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003;125(4):1203–18.CrossRefPubMed
71.
Naniche D, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67(10):6025–32.PubMedPubMedCentral
72.
Domingo-Musibay E, et al. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Cancer Gene Ther. 2014;21(11):483–90.CrossRefPubMed
73.
Msaouel P, et al. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther. 2013;13(4):483–502.CrossRefPubMed
74.
Seya T, et al. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies. Leuk Lymphoma. 1994;12(5–6):395–400.CrossRefPubMed
75.
Nakamura T, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23(2):209–14.CrossRefPubMed
76.
77.
Hashimoto K, Ono N, Tatsuo H, Minagawa H, Takeda M, Takeuchi K, Yanagi Y. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J Virol. 2002;76(13):6743–9CrossRefPubMedPubMedCentral
78.
79.
Arney K. Could measles cure cancer? Uh, not exactly…. UK: Cancer Research; 2014.
80.
81.
Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65(21):9643–50.CrossRefPubMed
82.
Rahman MM, et al. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev. 2010;21(2–3):169–75.CrossRefPubMedPubMedCentral
83.
Bartee E, et al. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012;18(10):1540–51.CrossRefPubMedPubMedCentral
84.
85.
Thirukkumaran CM, et al. Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant. 2014;49(1):80–6.CrossRefPubMed
86.
Thirukkumaran CM, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood. 2003;102(1):377–87.CrossRefPubMed
87.
Stojdl DF, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6(7):821–5.CrossRefPubMed
88.
Lichty BD, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther. 2004;15(9):821–31.CrossRefPubMed
89.
Batenchuk C, et al. Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J. 2013;3:e123.CrossRefPubMedPubMedCentral
90.
Conrad DP, et al. Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin Cancer Res. 2013;19(14):3832–43.CrossRefPubMed
91.
Au GG, et al. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007;137(2):133–41.CrossRefPubMed
92.
Kishore J, Kishor D. Can Parvovirus B19 infection be naturally oncolytic: clinical findings raise such a possibility in leukaemic children. Indian J Med Res. 2014;139(6):952–3.PubMedPubMedCentral
93.
Suzme R, et al. Sindbis viral vectors target hematopoietic malignant cells. Cancer Gene Ther. 2012;19(11):757–66.CrossRefPubMed
94.
Kim JH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006;14(3):361–70.CrossRefPubMed
95.
Wei X, et al. Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis. Oncol Rep. 2015;33(1):111–8.PubMed
96.
Miura Y, et al. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther. 2013;21(1):139–48.CrossRefPubMed
97.
Hu JC, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–47.CrossRefPubMed
98.
Esfandyari T, et al. Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. Mol Oncol. 2009;3(5–6):464–8.CrossRefPubMed
99.
Watanabe K, et al. Oncolytic adenovirus armed with cytokines enhances CAR-T cell efficacy in pancreatic tumor model. Mol Ther. 2016;24(S1):S205.
100.
Shaw AR, et al. Armed-ad gene therapy expressing PDL1 minibody enhances the anti-tumor effect of adoptively transferred chimeric antigen receptor T-cells for solid tumor treatment. Mol Ther. 2016;24(S1):P204.
Metadata
Title
Gene and virotherapy for hematological malignancies
Authors
Evidio Domingo-Musibay
Masato Yamamoto
Publication date
01-07-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2031-1

Other articles of this Issue 1/2016

International Journal of Hematology 1/2016 Go to the issue

Progress in Hematology

Gene editing and its application for hematological diseases

Letter to the Editor

Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia: should this be the first choice to establish the diagnosis of APL?

Case Report

Immunosuppressive therapy for patients with Down syndrome and idiopathic aplastic anemia

Original Article

Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles

Case Report

Transient ischemic attack as an unusual initial manifestation of acute promyelocytic leukemia

Case Report

Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits